Cargando…

Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy

BACKGROUND: One of the main goals of novel, noninvasive imaging techniques like high-resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM) is the prediction of treatment response for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitarokoili, Kalliopi, Sturm, Dietrich, Labedi, Adnan, Greiner, Tineke, Eitner, Lynn, Kumowski, Nina, Enax-Krumova, Elena K., Fisse, Anna Lena, Maier, Christoph, Gold, Ralf, Tegenthoff, Martin, Schmidt-Wilcke, Tobias, Yoon, Min-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582292/
https://www.ncbi.nlm.nih.gov/pubmed/31244899
http://dx.doi.org/10.1177/1756286419855485
_version_ 1783428292816142336
author Pitarokoili, Kalliopi
Sturm, Dietrich
Labedi, Adnan
Greiner, Tineke
Eitner, Lynn
Kumowski, Nina
Enax-Krumova, Elena K.
Fisse, Anna Lena
Maier, Christoph
Gold, Ralf
Tegenthoff, Martin
Schmidt-Wilcke, Tobias
Yoon, Min-Suk
author_facet Pitarokoili, Kalliopi
Sturm, Dietrich
Labedi, Adnan
Greiner, Tineke
Eitner, Lynn
Kumowski, Nina
Enax-Krumova, Elena K.
Fisse, Anna Lena
Maier, Christoph
Gold, Ralf
Tegenthoff, Martin
Schmidt-Wilcke, Tobias
Yoon, Min-Suk
author_sort Pitarokoili, Kalliopi
collection PubMed
description BACKGROUND: One of the main goals of novel, noninvasive imaging techniques like high-resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM) is the prediction of treatment response for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: A total of 17 patients with CIDP were examined prospectively at baseline and every 9 months over a period of 18 months using CCM to quantify corneal nerve degeneration markers and immune cell infiltration as well as HRUS to detect changes of the cross-sectional area (CSA) of the peripheral nerves. Additionally, skin biopsy of the distal and proximal leg as well as quantitative sensory testing were performed at the first follow-up visit. RESULTS: A value of more than 30 total corneal cells/mm(2) in CCM at baseline identified patients with clinical progression with a sensitivity/specificity of 100% in our cohort. Corneal nerve fiber density and length remained low and stable over the study period and intra-epidermal fiber density was markedly reduced in the majority of the patients. Furthermore, an increase in Bochum ultrasound score (BUS), which summarizes the CSA of the ulnar nerve in Guyons’ canal, the ulnar nerve in the upper arm, the radial nerve in the spiral groove and the sural nerve between the gastrocnemius muscle, and a maximum BUS of 4 at study initiation identified patients with disease progression (sensitivity 80%, specificity 88%). CONCLUSIONS: BUS and corneal total cell infiltration seem to represent early markers for clinical progression in CIDP, thus having the potential to identify at-risk patients and impact treatment decisions.
format Online
Article
Text
id pubmed-6582292
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65822922019-06-26 Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy Pitarokoili, Kalliopi Sturm, Dietrich Labedi, Adnan Greiner, Tineke Eitner, Lynn Kumowski, Nina Enax-Krumova, Elena K. Fisse, Anna Lena Maier, Christoph Gold, Ralf Tegenthoff, Martin Schmidt-Wilcke, Tobias Yoon, Min-Suk Ther Adv Neurol Disord Advances in Neuroimaging BACKGROUND: One of the main goals of novel, noninvasive imaging techniques like high-resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM) is the prediction of treatment response for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). METHODS: A total of 17 patients with CIDP were examined prospectively at baseline and every 9 months over a period of 18 months using CCM to quantify corneal nerve degeneration markers and immune cell infiltration as well as HRUS to detect changes of the cross-sectional area (CSA) of the peripheral nerves. Additionally, skin biopsy of the distal and proximal leg as well as quantitative sensory testing were performed at the first follow-up visit. RESULTS: A value of more than 30 total corneal cells/mm(2) in CCM at baseline identified patients with clinical progression with a sensitivity/specificity of 100% in our cohort. Corneal nerve fiber density and length remained low and stable over the study period and intra-epidermal fiber density was markedly reduced in the majority of the patients. Furthermore, an increase in Bochum ultrasound score (BUS), which summarizes the CSA of the ulnar nerve in Guyons’ canal, the ulnar nerve in the upper arm, the radial nerve in the spiral groove and the sural nerve between the gastrocnemius muscle, and a maximum BUS of 4 at study initiation identified patients with disease progression (sensitivity 80%, specificity 88%). CONCLUSIONS: BUS and corneal total cell infiltration seem to represent early markers for clinical progression in CIDP, thus having the potential to identify at-risk patients and impact treatment decisions. SAGE Publications 2019-06-18 /pmc/articles/PMC6582292/ /pubmed/31244899 http://dx.doi.org/10.1177/1756286419855485 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Advances in Neuroimaging
Pitarokoili, Kalliopi
Sturm, Dietrich
Labedi, Adnan
Greiner, Tineke
Eitner, Lynn
Kumowski, Nina
Enax-Krumova, Elena K.
Fisse, Anna Lena
Maier, Christoph
Gold, Ralf
Tegenthoff, Martin
Schmidt-Wilcke, Tobias
Yoon, Min-Suk
Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
title Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
title_full Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
title_fullStr Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
title_full_unstemmed Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
title_short Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
title_sort neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy
topic Advances in Neuroimaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582292/
https://www.ncbi.nlm.nih.gov/pubmed/31244899
http://dx.doi.org/10.1177/1756286419855485
work_keys_str_mv AT pitarokoilikalliopi neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT sturmdietrich neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT labediadnan neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT greinertineke neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT eitnerlynn neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT kumowskinina neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT enaxkrumovaelenak neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT fisseannalena neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT maierchristoph neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT goldralf neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT tegenthoffmartin neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT schmidtwilcketobias neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy
AT yoonminsuk neuroimagingmarkersofclinicalprogressioninchronicinflammatorydemyelinatingpolyradiculoneuropathy